NASDAQ:ZVSA ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis $0.23 -0.02 (-7.27%) As of 09:46 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ZyVersa Therapeutics Stock (NASDAQ:ZVSA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ZyVersa Therapeutics alerts:Sign Up Key Stats Today's Range$0.22▼$0.2550-Day Range$0.14▼$0.7852-Week Range$0.12▼$3.96Volume12,665 shsAverage Volume3.74 million shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. Read More ZyVersa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreZVSA MarketRank™: ZyVersa Therapeutics scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ZyVersa Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ZyVersa Therapeutics are expected to decrease in the coming year, from ($22.70) to ($46.10) per share.Price to Book Value per Share RatioZyVersa Therapeutics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ZyVersa Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.24% of the float of ZyVersa Therapeutics has been sold short.Short Interest Ratio / Days to CoverZyVersa Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in ZyVersa Therapeutics has recently increased by 2,541.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZyVersa Therapeutics does not currently pay a dividend.Dividend GrowthZyVersa Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.24% of the float of ZyVersa Therapeutics has been sold short.Short Interest Ratio / Days to CoverZyVersa Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in ZyVersa Therapeutics has recently increased by 2,541.61%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentZyVersa Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ZyVersa Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for ZVSA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ZyVersa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.21% of the stock of ZyVersa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.91% of the stock of ZyVersa Therapeutics is held by institutions.Read more about ZyVersa Therapeutics' insider trading history. Receive ZVSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ZVSA Stock News HeadlinesZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D ProgressJuly 21, 2025 | globenewswire.comZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading ThursdayJuly 16, 2025 | marketwatch.comElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by 2025, robots will shift from novelty to necessity — disrupting nearly every industry in their path. But one overlooked sector could become the real winner… and one little-known company may be the best way to get ahead of the boom.July 30 at 2:00 AM | Weiss Ratings (Ad)ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | MorningstarJuly 9, 2025 | morningstar.comMZyVersa’s VAR 200 approved for emergency use in rare kidney diseaseJuly 9, 2025 | uk.investing.comZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - NasdaqJuly 9, 2025 | nasdaq.comWhy Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?July 8, 2025 | benzinga.comZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross ProceedsJuly 8, 2025 | globenewswire.comSee More Headlines ZVSA Stock Analysis - Frequently Asked Questions How have ZVSA shares performed this year? ZyVersa Therapeutics' stock was trading at $1.06 on January 1st, 2025. Since then, ZVSA shares have decreased by 78.0% and is now trading at $0.2335. How were ZyVersa Therapeutics' earnings last quarter? ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) issued its earnings results on Monday, May, 12th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.33. When did ZyVersa Therapeutics' stock split? ZyVersa Therapeutics shares reverse split on Friday, April 26th 2024.The 1-10 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of ZyVersa Therapeutics? Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ZyVersa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ZyVersa Therapeutics investors own include Tesla (TSLA), Lucid Group (LCID), NVIDIA (NVDA), XPeng (XPEV), Akebia Therapeutics (AKBA), JPMorgan Chase & Co. (JPM) and Eli Lilly and Company (LLY). Company Calendar Last Earnings5/12/2025Today7/30/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZVSA CIK1859007 Webwww.zyversa.com Phone754-231-1688FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-109.54% Return on Assets-43.95% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.40 per share Price / Book0.07Miscellaneous Outstanding Shares4,870,000Free Float4,863,000Market Cap$1.14 million OptionableNot Optionable Beta0.82 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ZVSA) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.